Pan-London Perinatal Mental Health:

Guidance for Newborn Assessment

The Pan-London Perinatal Mental Health Network and the London Neonatal Operational Delivery Network

June 2017

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Review Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>29/06/2017</td>
<td>29/12/2017</td>
</tr>
</tbody>
</table>
Forword

This document aims to provide guidance for health care professionals involved in the care of babies born to women who have taken medication for mental disorders (psychotropic medication) during pregnancy. The decision to create such a document arose from discussions between the Pan-London Perinatal Mental Health Network and the London Neonatal Operational Delivery Network. It reflected the need for maternity, neonatal and mental health professionals to deliver consistent advice to parents and health professionals and to have a consistent approach to the assessment of babies who have been exposed to psychotropic medication in utero. The resulting document has been the work of a multi-disciplinary group who addressed the project with energy, thoughtfulness and diligence. We hope that it proves useful for practitioners and that it contributes to improving the outcome for mothers and their babies.

Liz McDonald
Consultant Perinatal Psychiatrist
Chair of the Pan-London PMH Network (2014-2017)
The impact of mental illness in pregnancy and following child birth is far reaching. It is essential that health professionals caring for parents and their babies work together. This guidance brings a much needed focus to the care of a baby whose mother has taken psychotropic medication in pregnancy, or whilst breastfeeding. It sets out clearly what is needed in the assessment and management of mother and child, the roles and responsibilities of the professionals involved and how information should be shared in relation to this aspect of their care. This guidance should form part of routine practice, ensuring families receive the best possible care.

Dr Sarah Taha
Consultant Perinatal Psychiatrist
Chair Pan-London PMH Network (Current)
Executive Summary

This document is to provide guidance for health care professionals involved in the care of babies born to women who have taken medication for mental disorders (psychotropic medication) during pregnancy. Its aim is to optimise and standardise the care of exposed babies and to provide guidance to health professionals (in particular neonatologists, paediatricians and midwives) on the appropriate assessment and management of the risks and needs of the newborn baby.

Any psychotropic medication that has been taken by the mother during her pregnancy and / or delivery should be documented in the baby’s notes. Babies who have been exposed to such medication should undergo a relevant assessment as set out in this document. This assessment will take place in the hospital, birthing unit or home (if home birth). Information on this process should be given to mothers during their pregnancy and at the time of the post-birth assessment, so they can feel confident about their baby’s wellbeing.
Authors

Dr Liz McDonald  Consultant Perinatal Psychiatrist, Clinical Lead for Perinatal Psychiatry Training, RCPsych
Jane Bass  Women’s Services Pharmacist, Guy’s and St Thomas’ NHS Trust
Jill Demilew  Consultant Midwife in Public Health, King’s College Hospital NHS Trust
Dr Kuljit Hunjan  ST4-6, South London and Maudsley Trust
Jenni Jagodzinski  Pan London Lead Nurse, London Neonatal Operational Delivery Network
Dr Zoe Kantor  CT1-3, UCLH
Dr Judith Meek  Consultant Neonatologist, UCLH and Honorary Senior Lecturer, UCL

Thanks to:

Jessica Bolton  Junior Project Manager, London Neonatal ODN
Peta Crisp  London Perinatal Mental Health Network and Training Administrator
Jo Maitland  Perinatal Mental Health Training and Service Development Lead & London Perinatal Mental Health Network Coordinator, Tavistock and Portman NHS Foundation Trust
Miss Louise Page  Consultant Obstetrician, Chelsea & Westminster Hospital NHS Foundation Trust - West Middlesex site
Susanne Sweeney  Network Director, London Neonatal ODN
Dr Angelika Wieck  Consultant Perinatal Psychiatrist, Manchester
# Table of Contents

- Foreword .................................................................................................................................................. 2  
- Executive Summary .................................................................................................................................. 4  
- Authors .................................................................................................................................................... 5  
- 1. Introduction ........................................................................................................................................... 7  
- 2. General Principles ................................................................................................................................... 8  
- 3. Components of the Newborn Assessment .......................................................................................... 10  
- 4. Interventions ......................................................................................................................................... 11  
- 5. Communication with Mother/Parents .................................................................................................. 13  
- 6. Psychotropic Medication: General Principles .................................................................................... 15  
- 7. Table of Issues to be considered with Individual Classes of Psychotropic Medication .................. 17  
  - Resources ................................................................................................................................................. 26  
  - Glossary ................................................................................................................................................... 29  
  - Appendix 1 ............................................................................................................................................... 31  
  - Appendix 2 ............................................................................................................................................... 33
1. Introduction

This document sets out to standardise and optimise the care given to newborn term babies when their mothers have taken psychotropic medication during pregnancy.

Ideally, a woman’s history of taking psychotropic medication should be asked about in pregnancy and during delivery and documented in her records. When knowledge of the fetus/baby being exposed is identified, a tailored assessment of the newborn baby should be planned for and instigated following delivery. The mother should be provided with information during pregnancy about the assessment process for her newborn baby to both inform her of what to expect and reassure her about her baby’s wellbeing.

This guidance is to ensure that both the relevant professionals are aware of the needs and risks of the exposed baby and that the baby’s physical and emotional welfare is monitored and maintained.
2. General Principles

The general principles outlined below are to be considered for all babies who have been exposed to psychotropic medication in utero. They highlight the importance of history taking, communication and ensuring that the needs of the baby across all appropriate parameters are thought about and met.

1. Separation of a baby from his/her mother should only occur if there is an immediate risk of death or long-term impairment to the baby.

2. A prolonged stay in hospital may cause agitation and distress to the mother, so this must be avoided whenever possible.

3. The mother’s hand held records, medical notes and electronic records should always be read by the individual clinician carrying out the examination of the newborn. The clinician must be mindful of any type of alert placed on the mother’s records. Most neonatal units/labour wards will also hold local information/alerts for ‘high risk’ pregnancies in a separate folder available as a hard copy.

4. It should never be assumed that a baby is irritable or lethargic solely because of his/her mother’s medication. If a newborn baby has any signs or symptoms they must be appropriately investigated for underlying medical causes.

5. A medication history must be taken from the baby’s mother (including herbal and OTC medication). Consideration must also be given to secondary exposure from family members who smoke (tobacco and cannabis).

6. The clinician responsible for the assessment of the newborn should not advise the mother about her medication. This is the responsibility of the mother’s treating clinician i.e. the GP and/or psychiatrist. The mother’s medication must only be altered by the mother’s clinician or a psychiatrist following clinical discussion and consultation with the mother’s notes and care-plans. Stopping her medication can potentially cause a relapse with life threatening consequences for mother and for baby.

7. The mother must not be advised by the clinician assessing the baby to stop or alter medication in order to enable breastfeeding.
8. The midwives and obstetricians must be informed if on assessing the infant, the mother is believed to be unwell. The baby must not be discharged until the mother has been adequately assessed.

9. If there are concerns about a mother’s mental health or her psychotropic medication there should be a low threshold for calling the psychiatric liaison team or the on-call psychiatric team for advice.

10. The mother’s capacity to make decisions must always be assessed.

11. The clinician must ensure that there are no safeguarding issues and must not discharge the baby if he/she is concerned about safeguarding the baby or the mother.

12. Advice must be sought from a more senior clinician if the examining clinician has concerns.

13. Consideration should be given to including both parents in decision making.

14. Keep detailed and accurate records and be open with parents about what is documented.

15. The content of the notes/records and discharge summary must be clear and comprehensive.

16. There should be full communication with other professionals about the discharge plan.

17. Permission for information sharing should be obtained from the mother for general information sharing with the GP. If there are safeguarding concerns (new or in place) it is mandatory that these are shared with all relevant professionals and that they are documented in the baby’s notes and records. It is always advisable to inform the parents and work in partnership with them if possible, however the baby’s safety and wellbeing are the clinician’s prime concerns.
3. Components of the Newborn Assessment

The following areas need to be considered for all babies who have been exposed to psychotropic medication in utero.

1. The newborn baby check should be carried out within the first 24 hours after birth. Particular attention is to be paid to examination of the palate and cardiovascular system, and results of antenatal scans must be reviewed.

2. The care plan for babies who have been exposed to maternal antidepressant medication in utero and who go home after 24hrs or have been born at home should include reassessment for Poor Neonatal Adaptation Syndrome (PNAS)* on day two (see table, page 16).

3. If the baby has symptoms, such as poor feeding, lethargy or irritability he/she should be assessed and treated for possible sepsis and hypoglycaemia, polycythaemia etc. It must not be assumed that the baby’s symptoms are solely due to withdrawing from or other effects of maternal medication (clinician prescribed or self-prescribed) or from psychoactive substances. Withdrawal is a diagnosis of exclusion.

4. Pulmonary hypertension is a rare complication of maternal SSRI use and will present with cyanosis. However, this may not yet be visible at the time of the routine assessment. Where available, pulse oximetry should be part of the cardiovascular assessment.

5. The clinician should be familiar with the antenatal plan for infant feeding before starting the baby check, and support the family with breastfeeding if this is appropriate and what the mother has planned for.

6. Admission to the neonatal unit or transitional care unit should be based on clinical need, rather than on the maternal psychiatric history.

7. Babies that are born in hospital can be discharged safely after 24 hours in the majority of cases.

*see glossary
4. Interventions

Interventions that need to be considered include physical assessment and monitoring of the baby, communication with the baby’s parents and healthcare practitioners, information sharing and consideration of any safeguarding concerns.

1. Pre-birth perinatal mental health care-plans. These are usually completed by 32 weeks gestation following a multi-disciplinary and multi-agency meeting which includes mother and partner/family and sets out current status and management plans relating to the physical aspects of the pregnancy and fetal development; the mental health problem and it’s treatment; the benefits and risks of treatment to fetus and mother; intra-partum care; breastfeeding and mental health assessment post-delivery/pre-discharge. These plans are held in the mother’s hand-held notes and distributed to the appropriate professionals and agencies as appropriate (e.g. midwifery, obstetrician, HV, GP, Perinatal Mental Health or community psychiatric team and children’s social care). Neonatology needs to be included in this distribution list. The clinician carrying out the assessment of the baby must read the care-plan before carrying out the assessment. These care-plans are used for women with the more severe mental disorders and will not be in place for a woman with for example mild to moderate depression/OCD on an SSRI (who make up the bulk of women with exposed fetuses). There may however be letters from the mental health clinician who sees the mother which sets out details of diagnosis and the management plan.

2. Monitoring wellbeing of baby. The plan for postnatal monitoring will depend upon the maternal medication the baby has been exposed to.

3. It is important to carry out general observations of feeding and wellbeing on all babies exposed to maternal medication.

4. Benzodiazepines and opiate withdrawal can begin 2-3 days after delivery, and so a longer observation period is necessary. Observation and withdrawal charts are commonly used for these babies to guide replacement therapy. This is usually carried out on a neonatal unit. Babies should not be separated from their mothers in anticipation of symptoms occurring.
5. Maximum support for breastfeeding must be given to the mother if safe and in accordance with her informed decision. Responsive formula feeding can also be supported if this is the mother’s informed decision. The mother should be encouraged and supported to hold the infant close, maintain eye contact and respond to her baby’s cues. Be aware that lack of sleep is a common precipitating factor for a relapse of severe psychiatric illness. Mixed feeding should be supported if this is the best way to protect the mother’s wellbeing as this will also protect the baby.

6. Discharge planning should include support for maternal and infant health, in particular supporting attachment between the mother and baby in the face of the challenges associated with a hard to settle baby:
   - It is vital to both the mother’s and the baby’s wellbeing that close contact between mother and baby continues in the home environment.
   - The mother and/or father/other carer should be shown how to comfort and hold the baby during periods when the baby is unsettled.
   - The practice of skin-to-skin contact should be promoted.
   - The use of a pacifier for non-nutritive sucking benefits may be advocated following consent from the mother/parent. This may help with comforting the baby and has been linked to helping reduce the risk of cot death.
   - Swaddling may help settle the baby, helping him/her feel warm and secure. This is recommended during the first 6-8 weeks of life only. A single light-weight sheet should be used and the use of blankets (including knitted ones) and hats indoors should be avoided to reduce over-heating and the risk of sudden infant death. Swaddling should not be too tight, with enough room for the baby to kick his/her feet. The baby should always be placed on his/her back to sleep.

7. Clear and timely information should be sent to the GP, health visitor and community midwife.

8. Relevant information should be written in the Parent’s Child Health Record (*the red book*) in paper or electronic format.

9. It must be ensured that there is careful documentation of the address the mother and baby are being discharged to and who they will be living with. This may be different from the booking address and there may be multiple addresses.

10. If there are safeguarding concerns the baby must be registered with a GP before being discharged from hospital (Laming, 2009)
5. Communication with Mother/Parents

Clear, compassionate communication with the mother and (if appropriate) the father of the baby is an essential part of the overall assessment.

1. The consultation with the mother should be undertaken in an open, compassionate and mindful manner holding in mind that stigma in relation to mental health problems may be a barrier to provision of good care, communication and help-seeking.

2. Communicate with the mother regarding the assessment of the baby, its outcome and any concerns raised by this or her own worries about the wellbeing of her baby.

3. Information should be given regarding the appropriate monitoring of the baby at home. This will include any warning signs the mother/parents need to be aware of and what action needs to be taken if needed.

4. It is important to appropriately reassure the mother about the wellbeing of her baby as this will enhance attachment with the baby.

5. It is important to inform the mother where and when she can and should seek help and to signpost her to the roles of the GP, health visitor, community midwife and A&E.

6. It should be acknowledged with the mother that it takes time to get to know one’s new baby.

7. The mother should be encouraged to seek support from her family and friends.

8. Communication with the father of the baby is important. Mother should be asked if she wishes father to be present for or advised about the assessment and its outcome. There can be complex relationship and communication issues between the parents of the baby, as well as legal and confidentiality issues. The clinician needs to be open with the mother and make a judgement about how to proceed when circumstances are difficult. Advice from a senior colleague should be sought if any uncertainty arises.

9. All mothers of babies who have been exposed to maternal antidepressants or psychotropic medications should receive a letter from the clinician completing the newborn examination informing them of the important symptoms to be aware of and any further action that needs to take place. The proforma for this letter can be found
This proforma should be personalised to each patient and shared with the health visitor, community midwife and GP (with mum’s consent).
6. Psychotropic Medication: General Principles

The following general principles apply to the understanding and planning of all assessments of the baby who has been exposed to psychotropic medication in utero.

1. Risks to the fetus related to medication include congenital defects, long-term neurobehavioural sequelae, neonatal adaptation syndrome, and withdrawal effects.
2. It is important to understand which congenital defects or other effects are associated with individual drugs and whether any congenital defects have been excluded by antenatal scans.
3. There are also risks to the fetus from untreated mental disorder in the mother.
4. There are significant benefits to the fetus from the mother being treated.
5. There are significant risks associated with suddenly stopping medication in the mother. Any risk to the mother is a risk to the infant.
6. Women with mental health conditions are more likely to be smokers. They also have significant exposure to other factors that affect the development of the fetus including obesity, poverty, social adversity, alcohol and substance misuse, childhood adversity and domestic abuse. These need to be assessed with respect to safeguarding.
7. Seek up to date advice regarding medication.
8. Women may be taking more than one psychotropic drug.
9. It is important to understand that advice on breastfeeding can be complex as the clinician needs to take into account factors that include the direct physiological effects of the medication on milk production and breastfeeding. The mother may have both an intellectual and emotional response to whether she can or cannot breastfeed or whether she is able to successfully breastfeed if she sets out to do so. Breastfeeding may have an effect on sleep and daily routine that may be detrimental for a mother with some of the more severe mental disorders.
10. Sedation in the mother due to medication needs to be taken into account. Many psychotropic medications have sedative properties including anti-psychotic, anti-depressant, mood stabilising, hypnotic and benzodiazepine drugs. It is important to
therefore understand what practical and emotional support the mother has in relation to feeding and caring for her baby in this context. The guidance to reduce the risk of cot death should be used to inform advice given to the mother and family.

11. A method for estimating risk to the baby from exposure to maternal psychotropic medication in breast milk is to calculate the Relative Infant Dose (RID). The RID is calculated by dividing the baby’s dose via milk (mg/kg/day) by the mother’s dose in mg/kg/day. If the RID is less than 10% most medications are considered safe to use. The RID of the vast majority of drugs is < 1%. The relative infant dose (RID) of each medication is found on the LactMed website: https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm

12. Some of the evidence for fetal malformations (first trimester of pregnancy) caused by drugs used for maternal mental health issues is conflicting. Interpreting the data in relation to risks to the newborn baby following exposure to maternal psychotropic medication can be difficult and confusing. Much of the information available has been obtained from studies that are retrospective with all of the issues that this method involves. Malformations and other problems in the newborn baby who has been exposed are more likely to be reported than when the outcome is normal and the baby healthy, as there is increased vigilance in women taking medication. This also applies to studies that look at larger populations. Increased screening for malformations among babies exposed in pregnancy to a drug can lead to increased detection. This may mean that minor malformations that are of no clinical significance are reported and the literature may not always differentiate between minor clinically insignificant malformations and more serious ones. Some of the data may come from studies where the medications are prescribed for non-psychiatric indications. More recently, there have been several studies on anti-depressants reporting on >100,000 exposures in pregnancy and even so, it has been difficult to draw firm conclusions about the effects on the developing fetus of the SSRIs.
7. Table of Issues to be considered with Individual Classes of Psychotropic Medication

<table>
<thead>
<tr>
<th>Class of drug</th>
<th>Examples</th>
<th>Assessment &amp; monitoring</th>
<th>Neonatal risks</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective Serotonin Reuptake Inhibitors (SSRIs)</td>
<td>citalopram escitalopram fluoxetine paroxetine sertraline</td>
<td>Confirm no congenital cardiac defects.</td>
<td>Statistical not clinical evidence of increased risk. Risk reduced when depression associated confounders adjusted for.</td>
<td>All present in milk but amount probably too low to be harmful.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Monitor for Poor Neonatal Adaptation Syndrome** (PNAS) (see end of table)</td>
<td>Central nervous system, motor, respiratory and gastrointestinal symptoms. The symptoms develop within 8 – 48 hours postpartum and fade within 72 hours.</td>
<td>RID* (Relative Infant Dose) (see end of table)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assess and monitor for Persistent Pulmonary Hypertension of the Newborn (PPHN).</td>
<td>Risk approx. 30/10,000 babies of mothers taking SSRIs beyond 20 weeks gestation (compared to background rate 20/10,000)</td>
<td>Citalopram 2-9% Escitalopram 5-8% Paroxetine &lt;2% Fluoxetine 3-12% Sertraline &lt;0.5%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Advice is to breastfeed unless other contraindications present.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Baby should be observed for sedation and adequate weight gain.</td>
</tr>
<tr>
<td>Serotonin and Noradrenaline Re-uptake Inhibitor (SNRI)</td>
<td>venlafaxine</td>
<td>Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1)</td>
<td>Central nervous system, motor, respiratory and gastrointestinal symptoms. The symptoms develop within 8 – 48 hours</td>
<td>The RID is greater than that for the SSRIs but remains &lt;10%. Advice is to breastfeed unless other contraindications present.</td>
</tr>
</tbody>
</table>
| Tricyclic Antidepressants (TCAs) | amitriptyline | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Confirm for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
|--------------------------------|---------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Tricyclic Antidepressants (TCAs) | clomipramine  |HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
| Tricyclic Antidepressants (TCAs) | dosulepin    |HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
| Tricyclic Antidepressants (TCAs) | doxepin      |HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
| Tricyclic Antidepressants (TCAs) | imipramine   |HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
| Tricyclic Antidepressants (TCAs) | lofepramine  |HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
| Tricyclic Antidepressants (TCAs) | nortriptyline|HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |
| Tricyclic Antidepressants (TCAs) | trimipramine |HZ | Confirm no congenital cardiac defects. (Poss statistical link with Clomipramine) | Monitor for Poor Neonatal Adaptation Syndrome (PNAS) (See appendix 1) | Low risk (amount in breast milk too small to be harmful) except doxepin (accumulation of metabolite may cause sedation and respiratory depression). | RID - Venlafaxine 4-15%  
Baby should be observed for sedation and adequate weight gain. |

**Monoamine Oxidase Inhibitors (MAOIs)**

| Monoamine Oxidase Inhibitors (MAOIs) | phenelzine | Confirm no congenital cardiac defects. | L
t little data available. | Lack of published data - avoid |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoamine Oxidase Inhibitors (MAOIs)</td>
<td>isocarboxazid</td>
<td>Confirm no congenital cardiac defects.</td>
<td>Little data available.</td>
<td>Lack of published data - avoid</td>
</tr>
<tr>
<td>Monoamine Oxidase Inhibitors (MAOIs)</td>
<td>tranylcypromine</td>
<td>Confirm no congenital cardiac defects.</td>
<td>Little data available.</td>
<td>Lack of published data - avoid</td>
</tr>
<tr>
<td>Monoamine Oxidase Inhibitors (MAOIs)</td>
<td>rarely prescribed</td>
<td>Confirm no congenital cardiac defects.</td>
<td>Little data available.</td>
<td>Lack of published data - avoid</td>
</tr>
</tbody>
</table>

**ANTIPSYCHOTICS**

**Indications:** schizophrenia; psychoses; mania and hypomania

<table>
<thead>
<tr>
<th>Class of drug</th>
<th>Examples</th>
<th>Assessment &amp; monitoring</th>
<th>Neonatal risks</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>First generation “typicals”</td>
<td>haloperidol</td>
<td>No current evidence that first generation anti-psychotics lead to malformations.</td>
<td>Anti-psychotics do enter the breastmilk. Levels are generally low and breastfeeding can be advised.</td>
<td></td>
</tr>
<tr>
<td>First generation “typicals”</td>
<td>chlorpromazine</td>
<td>No current evidence that first generation anti-psychotics lead to malformations.</td>
<td>Anti-psychotics do enter the breastmilk. Levels are generally low and breastfeeding can be advised.</td>
<td></td>
</tr>
<tr>
<td>First generation “typicals”</td>
<td>promethazine</td>
<td>No current evidence that first generation anti-psychotics lead to malformations.</td>
<td>Anti-psychotics do enter the breastmilk. Levels are generally low and breastfeeding can be advised.</td>
<td></td>
</tr>
<tr>
<td>Drug</td>
<td>Assess and monitor for extra-pyramidal symptoms</td>
<td>Possible extra-pyramidal symptoms (EPS – abnormal muscle movements – hypertonia, tremor, dystonia, motor restlessness) and sedation.</td>
<td>Sedation</td>
<td>Assess level of alertness, waking for feeds, poor sucking</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td>----------</td>
<td>-------------------------------------------------------</td>
</tr>
<tr>
<td>flupenthixol</td>
<td></td>
<td></td>
<td></td>
<td>Observe infant for sedation and extrapyramidal symptoms. RID flupenthixol &lt;1%</td>
</tr>
<tr>
<td><strong>Second generation “atypicals”</strong></td>
<td>amisulpiride</td>
<td>No current evidence that the atypical anti-psychotics lead to malformations, apart from risperidone. Abnormal muscle movements, hypertonia, tremor, dystonia, motor restlessness</td>
<td>Sedation</td>
<td>Assess level of alertness, waking for feeds, poor sucking</td>
</tr>
<tr>
<td></td>
<td>aripiprazole</td>
<td></td>
<td></td>
<td>Low RID values for olanzapine and quetiapine. Moderate RID values for risperidone and aripiprazole. High RID values for amisulpride. No serious adverse effects reported. Monitor for drowsiness, irritability, motor abnormalities and poor feeding following exposure to these drugs especially if at high risk (e.g. premature or LBW babies) Do not breastfeed while on clozapine. Drug concentrates in breastmilk. Risk of agranulocytosis and seizures. Aripiprazole may lower prolactin levels, affecting milk supply.</td>
</tr>
<tr>
<td></td>
<td>clozapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>quetiapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>olanzapine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>risperidone</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### MOOD STABILISERS

**Indications:** treatment and prophylaxis of mania, bipolar disorder and recurrent depression; aggressive or self-harming behaviour, prevention of depressive episodes associated with bipolar disorder

<table>
<thead>
<tr>
<th>Class of drug</th>
<th>Examples</th>
<th>Assessment &amp; monitoring</th>
<th>Neonatal risks</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Lithium</strong></td>
<td>Lithium carbonate, Lithium citrate</td>
<td>Confirm no congenital cardiac defects Monitor for 48 hours post delivery Assessment of neonatal withdrawal syndrome Lethargy, flaccid muscle tone, hypotonia</td>
<td>Possibly associated with first trimester cardiac abnormalities (Ebstein’s anomaly and other cardiac defects) Lithium toxicity Hypothyroidism Hypoglycaemia</td>
<td>Generally contraindicated RID 11-42%</td>
</tr>
<tr>
<td><strong>Sodium valproate</strong></td>
<td>sodium valproate (valproic acid, Depakote)</td>
<td>Assess for congenital malformations</td>
<td>Early pregnancy exposure increases the risk of congenital malformations to approx. 10% and significant associations have been reported for spina bifida (an approximate 13-fold increased risk from approximately 0.09% in the general population to between 1% and 2%), atrial septal</td>
<td>There are relatively low levels of valproate in breast milk Women often taking in combination with other anticonvulsants which stimulate metabolism making RID highly variable and less meaningful. Some reports suggest 7-9%.</td>
</tr>
</tbody>
</table>

*Do not prescribe for mental health problems in women planning a pregnancy, pregnant or breastfeeding.*
| Carbamazepine | Assess for congenital malformations including spina bifida | Early pregnancy exposure to carbamazepine reported to be linked with an approximately two-fold increased rate of major congenital malformation (from around 2% to approximately 3.5–5%) | Carbamazepine has relatively high levels in breastmilk and breastfed babies have serum levels that are measurable. Most infants have had no adverse reactions, but sedation, poor sucking, withdrawal reactions and cases of hepatic dysfunction have been reported. If mother chooses to breastfeed then baby needs to be monitored for growth, development and liver function. |

- defects, cleft palate, hypospadias, polydactyly and craniosynostosis.
- There is a risk of serious developmental disorders up to 40%.
<table>
<thead>
<tr>
<th><strong>Possible increased risk of Haemorrhagic Disease of the Newborn (Vitamin K deficiency bleeding, VKDB).</strong> Give parenteral neonatal Vitamin K</th>
<th><strong>Calculation of RID is less meaningful as carbamazepine induces metabolism of other drugs and so RID is highly variable.</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamotrigine</td>
<td>Monitor for apnoea, rash, drowsiness, poor sucking.</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Newborn babies are particularly at risk for high plasma levels because their ability to metabolize the drug by glucuronidation is limited, plasma protein binding is relatively low, and maternal plasma and milk levels can rise dramatically in the immediate postpartum period if the dosage is not reduced to the pre-pregnancy dosage. However, breastfed infants should be carefully monitored for side effects such as apnoea, rash, drowsiness or poor sucking, including measurement of serum levels to rule out toxicity if there is a concern. Monitoring of the platelet count and liver function may also be advisable. If an infant rash</td>
</tr>
</tbody>
</table>
occurs, breastfeeding should be discontinued until the cause can be established.

**ANXIOLYTICS**

Indications: short term relief of severe anxiety; panic disorder resistant to antidepressant therapy; insomnia (short term use), acute behavioural disturbance

<table>
<thead>
<tr>
<th>Class of drug</th>
<th>Examples</th>
<th>Assessment &amp; monitoring</th>
<th>Neonatal risks</th>
<th>Breastfeeding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzodiazepines</td>
<td>Longer acting - diazepam, nitrazepam, flurazepam, alprazolam, chlordiazepoxide, clobazam, clonazepam</td>
<td>Neonatal adverse events are uncommon but should be used cautiously.</td>
<td>Monitor for irritability, tremors</td>
<td>Limited information on RID. Long acting are between 2-3% Temazepam – undetectable Oxazepam &lt;1% Lorazepam 8%</td>
</tr>
<tr>
<td>Shorter acting – lorazepam, loprazolam, lormetazepam, temazepam, oxazepam</td>
<td>Prolonged use near term, especially in high doses may increase risk of neonatal withdrawal syndrome</td>
<td>May lower Apgar score</td>
<td>Monitor and assess for hypothermia, lethargy, feeding difficulties, poor respiratory effort</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Respiratory depression and/or “floppy infant syndrome”</td>
<td>Observe sleeping habits, temperature stability, weight changes – nutritional support may be needed if sucking poorly.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Lorazepam has a short half-life relative to many other benzodiazepines and does not appear to cause adverse effects in breastfed infants with usual maternal dosages.

Clonazepam can cause sedation in breastfed infants, especially when given with other central nervous system depressants. Monitor the infant for drowsiness, adequate weight gain, and developmental milestones, especially in younger, exclusively breastfed infants and when using combinations of psychotropic drugs.

<table>
<thead>
<tr>
<th>Beta Blockers</th>
<th>propranolol</th>
<th>Assess for congenital malformations including cleft lip, palate, cardiac and neural tube.</th>
<th>No conclusive evidence of congenital abnormalities with beta-blockers.</th>
<th>Because of the low levels of propranolol in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. Studies during breastfeeding have found no adverse reactions in breastfed infants clearly attributable to propranolol. No special precautions are required.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Busiprone</strong></td>
<td>No data available</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Class of drug</td>
<td>Examples</td>
<td>Assessment &amp; monitoring</td>
<td>Neonatal risks</td>
<td>Breastfeeding</td>
</tr>
<tr>
<td>---------------</td>
<td>----------</td>
<td>-------------------------</td>
<td>----------------</td>
<td>---------------</td>
</tr>
<tr>
<td>‘Z’ drugs</td>
<td>zopiclone, zolpidem or zaleplon</td>
<td>Not associated with an increased risk of congenital malformations</td>
<td>Low levels of zolpidem and zaleplon in breastmilk and regarded as safe in breastfeeding. Observe for sedation. Little data on zopiclone. Use alternative.</td>
<td></td>
</tr>
</tbody>
</table>
Resources


LactMed. The database contains information on drugs and other chemicals to which breastfeeding mothers may be exposed.

Antenatal and postnatal mental health: clinical management and service guidance
CG192 June 2015
https://www.nice.org.uk/guidance/cg192/chapter/introduction

Antipsychotic use in pregnancy and the risk for congenital malformations.

Electronic Medicines Compendium
Summary of Product Characteristics for individual drugs
www.medicines.org.uk

Guideline for the Examination of the palate
RCPCH

HEE PMH Programme
Online modules
http://www.e-lfh.org.uk/programmes/perinatal-mental-health/

Prenatal anti-depressant exposure and child behavioural outcomes at 7 years of age: A study within the Danish National Birth Cohort
Prenatal exposure to antidepressants and persistent hypertension of the newborn; systematic review and meta-analysis
Gregoridias, 2014
http://www.bmj.com/content/348/bmj.f6932

Selective serotonin reuptake inhibitors and risk for major congenital anomalies

SIGN 127: Management of Perinatal Mood Disorders
March 2012
http://www.sign.ac.uk/pdf/sign127.pdf

UNICEF UK Baby Friendly Initiative
Breastfeeding assessment tools for mothers, midwives and HV’s.

The Breastfeeding Network (BfN)
An independent source of support and information for breastfeeding women and others.
https://www.breastfeedingnetwork.org.uk/breastfeeding-ad-perinatal-mental-health/

The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis

The Lancet, Perinatal Mental Health, Series 1

The Lancet, Perinatal Mental Health, Series 2
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(14)61278-2.pdf
The Lullaby Trust
Safer sleeping and SIDs information
https://www.lullabytrust.org.uk/LThome

The Maudsley Prescribing Guidelines in Psychiatry 12th Edition
Wiley-Blackwell, David Taylor, Carol Paton, and Shitij Kapur
ISBN: 978-1-118-75460-3

The Protection of Children in England: A Progress Report
12 March 2009, Lord Laming
Glossary

Mental Disorders. Any disorder or disability of the mind, for example: psychosis, depression, mania, personality disorder, substance misuse.

Poor Neonatal Adaptation Syndrome (PNAS). The aetiology of anti-depressant induced Poor Neonatal Adaptation Syndrome remains unclear. Some argue that it is due to intoxication, others that it is a withdrawal syndrome and others that it is a bit of both (initial intoxication followed by withdrawal). Estimates are that between 25-30% of infants exposed to SSRIs in the late third trimester are at risk for this syndrome. No treatment intervention is usually required. The baby’s symptoms occur between 8 - 48 hours following birth and resolve often by 72 hours. This has implications for how long babies should be observed for the emergence of symptoms. If a baby does not display symptoms shortly after birth they may develop later. Given all this, a practical approach is to reassure women that if PNAS occurs, it is mostly mild. If they are at home and become concerned they should be advised to ask the Community Midwife or GP for advice and in emergencies attend A&E.

Symptoms can include: insomnia, restless sleep, needing to be awakened for feeds, poor sucking, irritability, vomiting, diarrhoea, agitation, tremors, jitteriness, shivering, hyperreflexia, decreased tone, increased tone, fever, hypothermia, temperature instability, hypoglycaemia, increased respiratory rate, respiratory distress, nasal congestion and acrocyanosis. The baby must be monitored for central nervous system, motor, respiratory and gastrointestinal symptoms. Check oxygen saturation according to local protocol. The syndrome appears to be worse with paroxetine than the other SSRIs. If the baby has a normal examination and has established feeding well, then she/he can go home or stay at home (if a home birth). Follow up studies have shown that at 2, 4, 6, and 8 months of age, exposed infants are indistinguishable from control infants without known exposure.

Psychoactive substances. Substances that, when taken in or administered into one's system, affect mental processes e.g. cognition or affect.
**Psychotropic medication.** Medication that is used to treat the symptoms of a mental disorder, for example: anxiety, low mood, paranoia, hallucinations, delusions, sleep problems etc.

**Relative Infant Dose (RID).** A method for estimating risk to the baby from exposure to maternal psychotropic medication in breast milk is to calculate the RID. The RID is calculated by dividing the baby’s dose via milk (mg/kg/day) by the mother’s dose in mg/kg/day. If the RID is less than 10% most medications are considered safe to use. The RID of the vast majority of drugs is < 1%. The relative infant dose (RID) of each medication is found on the LactMed website [https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm](https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm).

**Term Baby.** A baby born from 37 complete weeks gestation i.e. gestation of 37 weeks + 0 days onwards or at or more than 259 days (source: NICE Guideline NG25 November 2015 Preterm labour and birth).
Appendix 1

Letter to the mother and community healthcare practitioners:

**Baby details:**

Name

NHS number

Hosp Number

DOB

Discharge address and phone number

Looked after child: yes/no

**Mother’s details:**

Name

NHS number

Hosp Number

DOB

Discharge address and phone number

**Main carer (if not mother):**

Name

DOB

Discharge address and phone number
Baby has been exposed during the pregnancy to the following psychotropic medication
1. 
2. 
3. 

Breastfeeding is/ not contraindicated

The following signs may be observed and the baby will need to be supported with skin to skin care, gentle swaddling etc.
1. 
2. 
3. 

If at any time the baby appears unwell, drowsy or has feeding difficulties they should be referred to the local paediatric team for rapid assessment.

Professionals involved:

Follow up plans:
Appendix 2

Patient information sheet for women whose babies have been exposed to psychotropic medication in utero:

*I need to take medication for my mental health during pregnancy – what does this mean when my baby is born?*

Women need to take medication for many different physical and mental health problems during pregnancy. You have been given this leaflet as you and your doctor decided that it would be safest for you to take medication for your mental health during pregnancy. This includes antidepressants, antipsychotics and anti-anxiety medications. Some babies can experience symptoms after birth because of these medicines. For this reason your baby will have a physical health check within 24 hours of birth. You should not worry about this – even if babies do develop symptoms these usually settle down within a few days without the need for any treatment.

**Do I need to do anything when I am pregnant?**
- Make sure you tell the people involved in your care what medication you are taking
- Don’t stop or make any changes to your medication without talking to your doctor first
- Take medication regularly and make sure you don’t run out – if this happens make sure you talk to your GP or psychiatry doctor about what to do
- Your doctor will tell you about any symptoms your baby might experience

**What about after my baby is born?**
- If you give birth in hospital a doctor will check your baby just after birth (usually within the first 24 hours) to make sure that he/she is not experiencing any physical health problems
- The reviews will include checking your baby’s alertness and looking for any signs of irritability or distress, testing his/her movements for any stiffness or floppiness as well as listening to the baby’s heart and lungs
- The doctor will also ask if you have any worries about your baby’s wellbeing, including how he / she is settling, feeding and sleeping
- The check will take around 10 minutes and is not harmful or painful for your baby
During the check the doctor will talk to you about any concerns they find with your baby, and whether these are due to medication or other causes. They will explain any investigations or treatment needed.

The doctor will give you a letter telling you any symptoms you should look out for and what to do if your baby develops any of these.

If you have taken antidepressant medication in pregnancy and you go home from hospital within 24 hours, or have a home birth, your baby will be examined again on the second day after birth by a midwife.

You will be supported to feed your baby whether you choose to breastfeed, bottle feed or mixed feed.

Who should I speak to if I'm worried about my baby's health?

- If you are worried about your baby, speak to your GP, midwife or health visitor.
- If at any time your baby appears unwell, drowsy or has feeding difficulties you should see your GP or take him/her to A&E.

Further information about medications in pregnancy can be found at:
BUMPS (Best Use of Medicines in Pregnancy) [www.medicinesinpregnancy.org/](http://www.medicinesinpregnancy.org/)
Royal College of Psychiatrists: [www.rcpsych.ac.uk/healthadvice/problemsdisorders/mentalhealthinpregnancy.aspx](http://www.rcpsych.ac.uk/healthadvice/problemsdisorders/mentalhealthinpregnancy.aspx)